Dataset Information

Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.

ABSTRACT:

Background

Myelin transcription factor 1 (MYT1) and its homologue MYT1-like (MYT1L) are the two main members of MYT/NZF family transcription factors, which are highly related, share a high degree of identity and show similar regulatory functions in neural development. There are evidences from several cytology experiments showing that MYT1 is associated with carcinoma.

Methodology/principal findings

In the present study, we genotyped 944 surgically resected gastric cancer patients by the SNaPshot method to explore the association of MYT1L rs17039396 polymorphism with survival of gastric cancer in a Chinese population. We found that cardia cancer patients carrying MYT1L rs17039396 GG genotype survived for a significantly shorter time than those carrying the GA genotype. This significance was enhanced in the dominant model (GG vs. GA/AA, log-rank P?=?0.001), suggesting a potential protect role of the variant A allele. Multivariate Cox regression analyses showed that the AG/GG genotypes were associated with a significantly decreased risk of death from gastric cancer (adjusted hazard ratio (HR)?=?0.57, 95% confidence interval (CI)?=?0.40-0.81). Stratification analyses further showed that such protective effect was statistically significant in subgroups of patients with tumor size ?5 cm (adjusted HR?=?0.34, 95%CI?=?0.19-0.64), well-moderate gastric cancer (adjusted HR?=?0.59, 95%CI?=?0.35-0.98), no lymph-node metastasis (adjusted HR?=?0.49, 95%CI?=?0.31-0.76), no distant metastasis (adjusted HR?=?0.59, 95%CI?=?0.41-0.84).

Conclusions/significance

In conclusion, these data represents the first demonstration that MYT1L rs17039396 variants could indentified as a favorable prognostic indicator for gastric cancer, particularly among the cardia gastric cancer. Further validation in other larger studies with different ethnic populations and functional evaluations are needed.

SUBMITTER: Zhang Y

PROVIDER: S-EPMC3756043 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.

Zhang Yangmei Y Zhu Haixia H Zhang Xunlei X Gu Dongying D Zhou Xichang X Wang Meilin M Cao Chunxiang C Zhang Xiaojing X Wu Xiaomin X Gong Weida W Tang Yongfei Y Zhou Jianwei J Tang Cuiju C Zhang Zhengdong Z Chen Jinfei J

PloS one 20130828 8

<h4>Background</h4>Myelin transcription factor 1 (MYT1) and its homologue MYT1-like (MYT1L) are the two main members of MYT/NZF family transcription factors, which are highly related, share a high degree of identity and show similar regulatory functions in neural development. There are evidences from several cytology experiments showing that MYT1 is associated with carcinoma.<h4>Methodology/principal findings</h4>In the present study, we genotyped 944 surgically resected gastric cancer patients ...[more]

PMID: 24015200

Similar Datasets

Project description:Background The incidence of lung cancer is growing fast in China, however, the prognosis remains dismal due to the limited therapeutic approaches. The “ret proto-oncogene mutation” (RET) fusions have been proven to be the driver gene in lung cancer development and the therapeutic target of several multi-target tyrosine kinase inhibitors. Methods We applied formalin-fixed, paraffin-embedded (FFPE) samples of 39 patients with non-small cell lung cancer (NSCLC) using the Lung Plasma panel covering 168 cancer-associated genes and performed capture-based targeted deep sequencing to identify the RET fusion partners and concurrent gene mutation with Miseq. The log-rank test was used to compare the survival difference of patients according to treatment strategies. Statistical analyses and graphs were performed using R language and GraphPad Prism. Results Most of the samples were advanced (stage IIIb and IV) lung adenocarcinomas (80.77%). KIF5B-RET fusions were identified in 52% of the samples and K15-E12 was the most common variant. 6 (15%) samples harbored concurrent TP53 mutation and 3 samples were positive with EGFR mutation including a mutation in exon 19. Of these patients included, ten received cabozantinib, two received anlotinib, and one received crizotinib. Two (20%; 0–45) samples achieved stable disease and two were progressed in the cabozantinib treated group. Median progression-free survival (PFS) was 4 months (95% CI: 3.2–4.8) and median overall survival (OS) was 25 months (95% CI: 1.5–48.5). Three (11.54%; 0–24) samples achieved partial response in patients without RET inhibitor treatment and 4 (15.38%; 2–29) were stable disease. The median PFS was 11 months (95% CI: 1.2–20.8). There was no significant difference in PFS and OS between groups with or without RET inhibitors treatment. Conclusion This study provided insight into the RET fusions patients treatment. The survival benefit of current RET inhibitors was limited. More precise and potent RET inhibitors should be developed in the near future.

Dataset Information

Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.

Background

Methodology/principal findings

Conclusions/significance

Publications

Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets